Free Trial

Qsemble Capital Management LP Takes Position in The Clorox Company (NYSE:CLX)

Clorox logo with Consumer Staples background

Qsemble Capital Management LP acquired a new stake in shares of The Clorox Company (NYSE:CLX - Free Report) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 5,610 shares of the company's stock, valued at approximately $914,000.

Several other institutional investors also recently bought and sold shares of CLX. Mizuho Securities USA LLC increased its holdings in shares of Clorox by 46,877.8% in the 3rd quarter. Mizuho Securities USA LLC now owns 4,500,000 shares of the company's stock valued at $733,095,000 after acquiring an additional 4,490,421 shares during the period. Nuance Investments LLC raised its holdings in Clorox by 150.6% in the second quarter. Nuance Investments LLC now owns 1,597,674 shares of the company's stock worth $218,035,000 after purchasing an additional 960,094 shares in the last quarter. Van ECK Associates Corp lifted its position in shares of Clorox by 2.2% during the third quarter. Van ECK Associates Corp now owns 1,492,717 shares of the company's stock valued at $237,372,000 after buying an additional 31,510 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Clorox by 14.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 961,387 shares of the company's stock valued at $131,200,000 after buying an additional 120,716 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of Clorox by 11.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 802,237 shares of the company's stock worth $109,483,000 after buying an additional 85,529 shares during the last quarter. 78.53% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Clorox news, EVP Angela C. Hilt sold 1,733 shares of the stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $165.52, for a total transaction of $286,846.16. Following the completion of the transaction, the executive vice president now owns 13,471 shares of the company's stock, valued at $2,229,719.92. This trade represents a 11.40 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.57% of the company's stock.

Clorox Stock Up 0.6 %

CLX stock opened at $167.34 on Wednesday. The Clorox Company has a 12 month low of $127.60 and a 12 month high of $171.35. The company has a market cap of $20.71 billion, a price-to-earnings ratio of 58.31, a PEG ratio of 3.13 and a beta of 0.41. The company has a current ratio of 1.00, a quick ratio of 0.62 and a debt-to-equity ratio of 11.08. The firm has a 50-day moving average of $162.84 and a two-hundred day moving average of $148.88.

Clorox (NYSE:CLX - Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.36 by $0.50. Clorox had a net margin of 4.78% and a return on equity of 316.08%. The firm had revenue of $1.76 billion for the quarter, compared to analysts' expectations of $1.64 billion. During the same quarter in the previous year, the company posted $0.49 EPS. The company's revenue was up 27.0% compared to the same quarter last year. As a group, analysts forecast that The Clorox Company will post 6.85 earnings per share for the current fiscal year.

Clorox Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 29th will be given a $1.22 dividend. The ex-dividend date of this dividend is Wednesday, January 29th. This represents a $4.88 dividend on an annualized basis and a yield of 2.92%. Clorox's dividend payout ratio is currently 170.03%.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on CLX. DA Davidson lifted their price target on shares of Clorox from $153.00 to $171.00 and gave the stock a "neutral" rating in a report on Monday, November 4th. BNP Paribas upgraded Clorox to a "strong sell" rating in a research note on Friday, September 6th. Barclays boosted their price target on Clorox from $137.00 to $139.00 and gave the stock an "underweight" rating in a research note on Friday, November 1st. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Clorox from $144.00 to $151.00 and gave the stock a "hold" rating in a research note on Friday, August 2nd. Finally, JPMorgan Chase & Co. raised their price target on shares of Clorox from $148.00 to $174.00 and gave the stock a "neutral" rating in a report on Friday, October 11th. Five analysts have rated the stock with a sell rating, ten have issued a hold rating and one has given a buy rating to the company. According to MarketBeat.com, Clorox currently has a consensus rating of "Hold" and a consensus price target of $155.00.

Read Our Latest Stock Analysis on Clorox

Clorox Profile

(Free Report)

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

Featured Stories

Institutional Ownership by Quarter for Clorox (NYSE:CLX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should you invest $1,000 in Clorox right now?

Before you consider Clorox, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clorox wasn't on the list.

While Clorox currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

MicroStrategy Stock: Riding Bitcoin’s Wave to New Highs
How Abacus Life is Transforming Life Insurance into Assets | MarketBeat CEO Series
NVIDIA Earnings: Can Blackwell Propel the Stock to $200+ in 2025?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines